Pedia-Lax Chewable Tablets Disease Interactions
There are 3 disease interactions with Pedia-Lax Chewable Tablets (magnesium hydroxide).
Laxatives (applies to Pedia-Lax Chewable Tablets) inflammatory bowel disease
Major Potential Hazard, Moderate plausibility.
The use of laxatives is contraindicated in patients with inflammatory bowel disease. Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.
References (6)
- (2001) "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc
- "Product Information. Fleet Bisacodyl (bisacodyl)." Fleet
- "Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb
- (2001) "Product Information. Neoloid (castor oil)." Paddock Laboratories Inc
- (2022) "Product Information. SenoSol-X (senna)." Apothecon Inc
- (2010) "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories
Laxatives (applies to Pedia-Lax Chewable Tablets) intestinal obstruction disorders
Major Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Obstruction
The use of laxatives is contraindicated in patients with intestinal obstruction disorders. Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation. Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.
References (8)
- (2001) "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc
- "Product Information. Fleet Bisacodyl (bisacodyl)." Fleet
- "Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb
- (2001) "Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet
- (2001) "Product Information. Citrucel (methylcellulose)." SmithKline Beecham
- (2001) "Product Information. Fleet Babylax (glycerin)." Alcon Laboratories Inc
- (2022) "Product Information. SenoSol-X (senna)." Apothecon Inc
- (2010) "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories
Magnesium salts (applies to Pedia-Lax Chewable Tablets) renal dysfunction
Major Potential Hazard, High plausibility.
Magnesium is eliminated by the kidney. The serum concentration of magnesium is increased in patients with renal impairment. Magnesium toxicity includes CNS depression, muscular paralysis, respiratory depression, hypotension and prolonged cardiac conduction time. Disappearance of the patellar reflex is a useful clinical sign of magnesium intoxication. Therapy with magnesium should be administered cautiously and dosages should be modified in patients with compromised renal function. Clinical monitoring of serum magnesium levels is recommended.
References (5)
- (2001) "Product Information. Mag-Ox 400 (magnesium oxide)." Blaine Company Inc.
- (2001) "Product Information. Uro-Mag (magnesium oxide)." Blaine Company Inc.
- (2001) "Product Information. Slow-Mag (magnesium chloride)." Searle
- (2001) "Product Information. Magonate (magnesium gluconate)." Fleming and Company
- (2001) "Product Information. Losospan (magaldrate)." Whitehall-Robbins
Switch to consumer interaction data
Pedia-Lax Chewable Tablets drug interactions
There are 414 drug interactions with Pedia-Lax Chewable Tablets (magnesium hydroxide).
More about Pedia-Lax Chewable Tablets (magnesium hydroxide)
- Pedia-Lax Chewable Tablets consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Latest FDA alerts (2)
- Side effects
- Dosage information
- During pregnancy
- Drug class: antacids
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.